Storys zum Thema Pharma

Debiopharm International SA

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)

Lausanne, Switzerland and Atlanta, GA (ots) - Triptodur (TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing for children with CPP Approval brings new CPP treatment formulation ...

Debiopharm International SA

GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market

Québec, Canada (ots) - GenePOC announces the signing of an exclusive distribution agreement with Cardinal Health to become its commercial partner in the United States. GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to announce that it has signed an exclusive distribution agreement with Cardinal ...

Debiopharm International SA

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...

kENUP Foundation

European Investment Bank (EIB) supports Development and Production of Universal Flu Vaccine Candidate

Luxembourg, and Ness Ziona, Israel (ots) - - Cross reference: Picture is available at http://www.presseportal.de/pm/127019/3664051 - The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd., developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a EUR20 million loan ...

Debiopharm International SA

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...

Debiopharm International SA

GenePOC announces FDA clearance for revogene(TM) instrument and its GBS LB test

Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...

Debiopharm International SA

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...

Debiopharm International SA

Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen

Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...

Grünenthal Gruppe

Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward

Aachen, Germany (ots) - - Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and institutions - Grünenthal brings fully integrated R&D capabilities in pain to this community - there is no other company with so much focus on ...

Grünenthal Gruppe

Mark Fladrich appointed new Chief Commercial Officer (CCO) at Grünenthal

Aachen (ots) - The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017. Mark Fladrich ...

Debiopharm International SA

BC Platforms Closes USD $10 million Series B Financing led by Debiopharm and Tesi to accelerate knowledge platform development

Basel, Switzerland, Lausanne, Switzerland and Helsinki, Finland (ots) - Leading Big Data company developing platform with clinical and genomic data from 5 million subjects, to transform drug development and bring clinical benefits to patients. BC Platforms, a world leader in genomic data management solutions, today ...

Debiopharm International SA

Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Lausanne (ots) - Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group(TM) (www.debiopharm.com), announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically ...

Grünenthal Group

Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of CRPS

Aachen / Pisa (ots) - Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need - Neridronic acid is the first investigational medicine to receive Breakthrough Therapy ...

Grünenthal Group

Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease

Aachen, Germany / Pittsburgh, PA, USA (ots) - - The acquisition supports Grünenthal's commercial and R&D strategy to drive innovation in pain. - Thar Pharmaceutical's lead compound, T121, complements Grünenthal's existing development pipeline and the goal of delivering innovative and effective treatments to ...

B. Braun Melsungen AG

B. Braun Medical acquires Dismed's hand sanitizer and intravenous fluid businesses in South Africa / Commitment to growth and local manufacturing for the African healthcare sector

Melsungen/Johannesburg (ots) - On 30 June 2016, B. Braun Medical, the South African subsidiary of the German B. Braun Group, completed its acquisition of Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd, both out of business rescue. With over 600 employees in South Africa, B. Braun specialises in the ...

ITM Isotope Technologies Munich SE

Isotope Technologies Garching announces successful Validation of EndolucinBeta (TM) (n.c.a. Lutetium-177) Marketing Authorization Application by the European Medicines Agency

Garching (ots) - The ITM Group announced today that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) of the medicinal product EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients but will be used for ...

Max Lehner AG

Dersim Stein acquires full ownership of Max Lehner Holding AG

AmVac AG

New possibilities in the fight against pancreatic cancer

Zug, Switzerland (ots) - Licence extension in the contract between AmVac and the Helmholtz Centre for the adjuvant Malp-2 offers sustainable potential for patients, attending physicians and for pharmaceutical and medical research. Milestone thanks to licence extension The licence for Malp-2 was successfully extended in November 2014. The adjuvant can now be used for the first time for all preventive and therapeutic ...

European Society for Medical Oncology (ESMO)

ESMO announces annual medical oncology congress platform in Europe from 2016

Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...

Eckert & Ziegler Strahlen und Medizintechnik AG

Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer

Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...

TVM Capital

TVM Life Science Ventures VII Raises US $201.6 Million at Final Closing

Montreal/Munich (ots) - Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly TVM Capital Life Science, one of the leading life science venture capital firms in Canada, the United States and Europe, today announced the final closing of its latest ...

Grünenthal GmbH

Improved pain relief for patients with severe chronic low back pain - results of a new study show 37%* more pain relief with Palexia® (tapentadol PR) compared to oxycodone/naloxone PR

Aachen (ots) - EMBARGO: This information is for European healthcare professionals only. Not intended for UK audience. Low back pain is one of the most common chronic pain conditions. Studies have shown that up to 85% of people worldwide will suffer from back pain during their lives.(1) A high percentage of severe ...

Sanofi

Sanofi Announces Upcoming Launch of MyStar Connect®

Vienna, Austria (ots) - - MyStar Connect® software contributes to Sanofi's commitment in providing integrated diabetes care solutions, and supports healthcare professionals in clinical decision-making - - CE mark for MyStar Connect® - At the 50th annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the upcoming launch of ...

Grünenthal GmbH

New Palexia® study confirms effective pain relief in long-term use / Chronic pain patients benefit from long-term tapentadol treatment

Aachen (ots) - - EMBARGO: This information is for healthcare professionals only. Not intended for UK audience. - A recent study published in the medical journal "Current Medical Research and Opinion"* has results that are good news for chronic pain patients. This new trial was designed to meet real-life conditions ...